Abstract
A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Current Pharmaceutical Design
Title:In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles
Volume: 19 Issue: 41
Author(s): Soo-Jin Choi, Jae-Min Oh, Hae-Eun Chung, Seung-Hee Hong, In-Hoo Kim and Jin-Ho Choy
Affiliation:
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Abstract: A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Export Options
About this article
Cite this article as:
Choi Soo-Jin, Oh Jae-Min, Chung Hae-Eun, Hong Seung-Hee, Kim In-Hoo and Choy Jin-Ho, In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles, Current Pharmaceutical Design 2013; 19 (41) . https://dx.doi.org/10.2174/138161281941131219123718
DOI https://dx.doi.org/10.2174/138161281941131219123718 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Tumor Stroma Manipulation By MSC
Current Drug Targets HSP60 as a Drug Target
Current Pharmaceutical Design Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Gene Expression Studies in Multiple Sclerosis
Current Genomics Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Role of Anionic Polysaccharides in the Preparation of Nanomedicines with Anticancer Applications
Current Pharmaceutical Design Epigenetic Regulation of Osteogenic Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy 5-Lipoxygenase and Cyclooxygenase Inhibitory Dammarane Triterpenoid 1 from Borassus flabellifer Seed Coat Inhibits Tumor Necrosis Factor-α Secretion in LPSInduced THP-1 Human Monocytes and Induces Apoptosis in MIA PaCa-2 Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology A Closer Look at Protein Transduction Domains as a Tool in Drug Delivery
Current Nanoscience